Reduced N-Acetylaspartate Levels in the Frontal Cortex of 3,4-Methylenedioxymethamphetamine (Ecstasy) Users: Preliminary Results

References

1. ↵
   Schmidt CJ. Neurotoxicity of the psychedelic amphetamine, methylenedioxymethamphetamine. J Pharmacol Exp Ther 1987;240:1–7

   Abstract/FREE Full Text
2. Stone DM, Stahl DC, Hanson GR, Gibb JW. The effects of 3,4-methylenedioxymethamphetamine (MDMA) and 3,4-methylenedioxyamphetamine (MDA) on monoaminergic systems in the rat brain. Eur J Pharmacol 1986;128:41–48

   CrossRefPubMedWeb of Science
3. ↵
   Battaglia G, Yeh SY, O’Hearn E, Molliver ME, Kuhar MJ, De Souza EB. 3,4-Methylenedioxymethamphetamine and 3,4-methylenedioxyamphetamine destroy serotonin terminals in rat brain: quantification of neurodegeneration by measurement of [³H]paroxetine-labeled serotonin uptake sites. J Pharmacol Exp Ther 1987;242:911–916

   Abstract/FREE Full Text
4. Ricaurte GA, Forno LS, Wilson MA, et al. (+/−)3,4-Methylenedioxymethamphetamine selectively damages central serotonergic neurons in nonhuman primates. JAMA 1988;260:51–55

   CrossRefPubMedWeb of Science
5. ↵
   Ricaurte GA, Martello AL, Katz JL, Martello MB. Lasting effects of (+−)-3,4-methylenedioxymethamphetamine (MDMA) on central serotonergic neurons in nonhuman primates: neurochemical observations. J Pharmacol Exp Ther 1992;261:616–622

   Abstract/FREE Full Text
6. ↵
   O’Hearn E, Battaglia G, De Souza EB, Kuhar MJ, Molliver ME. Methylenedioxyamphetamine (MDA) and methylenedioxymethamphetamine (MDMA) cause selective ablation of serotonergic axon terminals in forebrain: immunocytochemical evidence for neurotoxicity. J Neurosci 1988;8:2788–2803

   Abstract
7. ↵
   Wilson MA, Ricaurte GA, Molliver ME. Distinct morphologic classes of serotonergic axons in primates exhibit differential vulnerability to the psychotropic drug 3,4-methylenedioxymethamphetamine. Neuroscience 1989;28:121–137

   CrossRefPubMedWeb of Science
8. ↵
   Peroutka SJ. Incidence of recreational use of 3,4-methylenedimethoxymethamphetamine (MDMA, “ecstasy”) on an undergraduate campus. N Engl J Med 1987;317:1542–1543

   PubMedWeb of Science
9. ↵
   McCann UD, Ridenour A, Shaham Y, Ricaurte GA. Serotonin neurotoxicity after (+/−)3,4-methylenedioxymethamphetamine (MDMA; “Ecstasy”): a controlled study in humans. Neuropsychopharmacology 1994;10:129–138

   CrossRefPubMedWeb of Science
10. ↵
    Ricaurte GA, Finnegan KT, Irwin I, Langston JW. Aminergic metabolites in cerebrospinal fluid of humans previously exposed to MDMA: preliminary observations. Ann N Y Acad Sci 1990;600:699–708

    PubMedWeb of Science
11. ↵
    Scheffel U, Szabo Z, Mathews WB, et al. In vivo detection of short- and long-term MDMA neurotoxicity–a positron emission tomography study in the living baboon brain. Synapse 1998;29:183–192

    CrossRefPubMedWeb of Science
12. ↵
    McCann UD, Szabo Z, Scheffel U, Dannals RF, Ricaurte GA. Positron emission tomographic evidence of toxic effect of MDMA (“Ecstasy”) on brain serotonin neurons in human beings. Lancet 1998;352:1433–1437

    CrossRefPubMedWeb of Science
13. Semple DM, Ebmeier KP, Glabus MF, O’Carroll RE, Johnstone EC. Reduced in vivo binding to the serotonin transporter in the cerebral cortex of MDMA (‘ecstasy’) users. Br J Psychiatry 1999;175:63–69

    Abstract/FREE Full Text
14. Reneman L, Booij J, de Bruin K, et al. Effects of dose, sex, and long-term abstention from use on toxic effects of MDMA. Lancet 2001;358:1864–1869

    CrossRefPubMedWeb of Science
15. ↵
    Reneman L, Reneman L, Lavalaye J, et al. Cortical serotonin transporter density and verbal memory in individuals who stopped using 3,4-methylenedioxymethamphetamine (MDMA or “Ecstasy”): preliminary findings. Arch Gen Psych 2001;58:901–906

    CrossRefPubMedWeb of Science
16. ↵
    Boot BP, McGregor IS, Hall W. MDMA (Ecstasy) neurotoxicity: assessing and communicating the risks. Lancet 2000;355:1818–1821

    CrossRefPubMedWeb of Science
17. ↵
    Topp L, Hando J, Dillon P, Roche A, Solowij N. Ecstasy use in Australia: patterns of use and associated harm. Drug Alcohol Depend 1999;55:105–115

    CrossRefPubMedWeb of Science
18. ↵
    Malberg JE, Seiden LS. Small changes in ambient temperature cause large changes in 3,4-methylenedioxymethamphetamine (MDMA)-induced serotonin neurotoxicity and core body temperature in the rat. J Neurosci 1998;18:5086–5094

    Abstract/FREE Full Text
19. ↵
    Howe FA, Maxwell RJ, Saunders DE, Brown MM, Griffiths JR. Proton spectroscopy in vivo. Magn Reson Q 1993;9:31–59

    PubMedWeb of Science
20. ↵
    Urenjak J, Williams SR, Gadian DG, Noble M. Proton nuclear magnetic resonance spectroscopy unambiguously identifies different neural cell types. J Neurosci 1993;13:981–989

    Abstract
21. ↵
    Higuchi T, Graham SH, Fernandez EJ, et al. Effects of severe global ischemia on N-acetylaspartate and other metabolites in the rat brain. Magn Reson Med 1997;37:851–857

    PubMed
22. ↵
    Bottomley PA. Spatial localization in NMR spectroscopy in vivo. Ann N Y Acad Sci 1987;508:333–348

    CrossRefPubMedWeb of Science
23. ↵
    Webb PG, Sailasuta N, Kohler SJ, Raidy T, Moats RA, Hurd RE. Automated single-voxel proton MRS: technical development and multisite verification. Magn Reson Med 1994;31:365–373

    PubMedWeb of Science
24. ↵
    Ernst T, Chang L, Leonido-Yee M, Speck O. Evidence for long-term neurotoxicity associated with methamphetamine abuse: a 1H MRS study. Neurology 2000;54:1344–1349

    Abstract/FREE Full Text
25. ↵
    Brownell AL, Jenkins BG, Elmaleh DR, Deacon TW, Spealman RD, Isacson O. Combined PET/MRS brain studies show dynamic and long-term physiological changes in a primate model of Parkinson disease. Nat Med 1998;4:1308–1312

    CrossRefPubMed
26. ↵
    Arnold DL, Riess GT, Matthews PM, et al. Use of proton magnetic resonance spectroscopy for monitoring disease progression in multiple sclerosis. Ann Neurol 1994;36:76–82

    CrossRefPubMedWeb of Science
27. ↵
    Cendes F, Andermann F, Dubeau F, Matthews PM, Arnold DL. Normalization of neuronal metabolic dysfunction after surgery for temporal lobe epilepsy: evidence from proton MR spectroscopic imaging. Neurology 1997;49:1525–1533

    Abstract/FREE Full Text
28. De Stefano N, Matthews PM, Antel JP, Preul M, Francis G, Arnold DL. Chemical pathology of acute demyelinating lesions and its correlation with disability. Ann Neurol 1995;38:901–909

    CrossRefPubMedWeb of Science
29. ↵
    Vion-Dury J, Nicoli F, Salvan AM, Confort-Gouny S, Dhiver C, Cozzone PJ. Reversal of brain metabolic alterations with zidovudine detected by proton localised magnetic resonance spectroscopy. Lancet 1995;345:60–61

    PubMed
30. ↵
    Hatzidimitriou G, McCann UD, Ricaurte GA. Altered serotonin innervation patterns in the forebrain of monkeys treated with (+/−)3,4-methylenedioxymethamphetamine seven years previously: factors influencing abnormal recovery. J Neurosci 1999;19:5096–5107

    Abstract/FREE Full Text
31. ↵
    McCann UD, Wong DF, Yokoi F, Villemagne V, Dannals RF, Ricaurte GA. Reduced striatal dopamine transporter density in abstinent methamphetamine and methcathinone users: evidence from positron emission tomography studies with [¹¹C]WIN-35,428. J Neurosci 1998;18:8417–8422

    Abstract/FREE Full Text
32. ↵
    Villemagne V, Yuan J, Wong DF, et al. Brain dopamine neurotoxicity in baboons treated with doses of methamphetamine comparable to those recreationally abused by humans: evidence from [¹¹C]WIN-35,428 positron emission tomography studies and direct in vitro determinations. J Neurosci 1998;18:419–427

    Abstract/FREE Full Text
33. ↵
    Chang L, Ernst T, Grob CS, Poland RE. Cerebral (1)H MRS alterations in recreational 3, 4-methylenedioxymethamphetamine (MDMA, “ecstasy”) users. J Magn Reson Imaging 1999;10:521–526

    CrossRefPubMedWeb of Science
34. ↵
    Chang L, Ernst T, Poland RE, Jenden DJ. In vivo proton magnetic resonance spectroscopy of the normal aging human brain. Life Sci 1996;58:2049–2056

    CrossRefPubMedWeb of Science
35. ↵
    Fowler JS, Volkow ND, Wang GJ, et al. Age-related increases in brain monoamine oxidase B in living healthy human subjects. Neurobiol Aging 1997;18:431–435

    CrossRefPubMedWeb of Science
36. ↵
    Tsai G, Coyle JT. N-acetylaspartate in neuropsychiatric disorders. Prog Neurobiol 1995;46:531–540

    CrossRefPubMedWeb of Science
37. ↵
    Rubin Y, LaPlaca MC, Smith DH, Thibault LE, Lenkinski RE. The effect of N-acetylaspartate on the intracellular free calcium concentration in NTera2-neurons. Neurosci Lett 1995;198:209–212

    CrossRefPubMedWeb of Science
38. ↵
    Bertolino A, Esposito G, Callicott JH, et al. Specific relationship between prefrontal neuronal N-acetylaspartate and activation of the working memory cortical network in schizophrenia. Am J Psychiatry 2000;157:26–33

    PubMedWeb of Science
39. ↵
    Reneman L, Majoie CBLM, Schmand B, van den Brink W, den Heeten GJ. Prefrontal N-acetylaspartate is strongly associated with memory performance in (abstinent) Ecstasy users: preliminary report. Biol Psych 2001;50:550–554

    CrossRefPubMedWeb of Science
40. ↵
    Reed LJ, Winstock A, Cleare AJ, McGuire P. Toxic effect of MDMA on brain serotonin neurons. Lancet 1999;353:1268–1271
41. ↵
    Van de Wijngaart G, Braam R, De Bruin D, Fris M, Maalsté N, Verbraeck H. Ecstasy in het uitgaanscircuit (Ecstasy and the Dutch Rave Scene: A Socio-epidemiological Study on the Nature and Extent of, and the Risks Involved in using Ecstasy and Other Party Drugs at Dance Events). Utrecht, the Netherlands: Addiction Research Institute;1997